Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Operating Leases (2019 - 2024)

VYNE Therapeutics (VYNE) has disclosed Operating Leases for 5 consecutive years, with $99000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Operating Leases fell 53.74% year-over-year to $99000.0, compared with a TTM value of $99000.0 through Dec 2024, down 53.74%, and an annual FY2024 reading of $99000.0, down 53.74% over the prior year.
  • Operating Leases was $99000.0 for Q4 2024 at VYNE Therapeutics, up from $25000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.4 million in Q1 2021 and bottomed at $25000.0 in Q2 2024.
  • Average Operating Leases over 4 years is $672636.4, with a median of $775000.0 recorded in 2021.
  • The sharpest move saw Operating Leases skyrocketed 334.55% in 2020, then crashed 53.74% in 2024.
  • Year by year, Operating Leases stood at $853000.0 in 2020, then decreased by 9.14% to $775000.0 in 2021, then tumbled by 72.39% to $214000.0 in 2023, then plummeted by 53.74% to $99000.0 in 2024.
  • Business Quant data shows Operating Leases for VYNE at $99000.0 in Q4 2024, $25000.0 in Q2 2024, and $63000.0 in Q1 2024.